Zydus Lifesciences Ltd received final USFDA approval for its generic Deflazacort oral suspension (22.75 mg/ml) on Monday. This medication treats Duchenne Muscular Dystrophy (DMD) in patients aged five and older by decreasing inflammation. The company plans to produce this steroid at Doppel, Italy.